Old Web
English
Sign In
Acemap
>
authorDetail
>
Matthias Ritgen
Matthias Ritgen
University of Cologne
Medicine
Minimal residual disease
Immunology
Fludarabine
Rituximab
5
Papers
444
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Standardized MRD Flow and ASO IGH RQ-PCR for MRD Quantification in CLL Patients after Rituximab-Containing Immunochemotherapy – a Comparative Analysis in 574 Samples from the Randomized GCLLSG CLL8 Trial
2008
Blood
Sebastian Boettcher
Stephan Stilgenbauer
R Busch
Monika Brüggemann
Thorsten Raff
Kirsten Fischer
Günter Fingerle-Rowson
Anna Maria Fink
Christiane Pott
Hartmut Döhner
Michael Hallek
Michael Kneba
Matthias Ritgen
Show All
Source
Cite
Save
Citations (1)
Chemoimmuno-Therapy with Fludarabine, Cyclophosphamide and Alemtuzumab in Patients with Relapsed/Refractory CLL: Interim Analysis of the CLL2L Trial of the German CLL Study Group
2008
Blood
Thomas Elter
Rojin James
Stephan Stilgenbauer
Matthias Ritgen
Michael Hallek
Andreas Engert
Show All
Source
Cite
Save
Citations (6)
Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG).
2007
Blood
Kirsten Fischer
Stephan Stilgenbauer
Carmen D. Schweighofer
Jasmin Renschler
R Busch
Michael Kiehl
Leopold Balleisen
Michael J. Eckart
Anna Maria Fink
Sebastian Boettcher
Matthias Ritgen
Michael Kneba
Peter Staib
Hartmut Doehner
Barbara Eichhorst
Michael Hallek
Clemens-Martin Wendtner
Show All
Source
Cite
Save
Citations (102)
1